Pegaspargase (Oncaspar); Calaspargase Pegol-mknl (Asparlas)
Defines medical necessity criteria, approval durations, dosing limits, contraindications, and coding guidance for coverage of Oncaspar and Asparlas for acute lymphoblastic leukemia and limited off-label T-cell lymphoma regimens across Commercial, HIM, and Medicaid lines of business.
4Q 2024 annual review: for T-cell lymphoma removed hepatosplenic T-cell lymphoma indication and added GELAD regimen option; references reviewed and updated.
Clarified age 1 month to <21 years for Asparlas per prescribing information.